ClinicalTrials.gg
CompletedNCT01702181Updated Jan 17, 2014

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

A Phase 1 interventional study of OPA-15406 and Tacrolimus in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-01-17.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
12th of 16
92 · median 177
Started
2012
the only one that year
Phase 1
2 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
2 of 16
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 1, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic Dermatitis, Eczema
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects 18-65 years of age
  • Diagnosis of atopic dermatitis (AD)
  • AD affecting at least 5% of total Body Surface Area (BSA) for Part 1 and at least 10% BSA for Part 2, not including face, neck, and head
  • Have had a positive but inadequate response to one or more treatment course of standard AD therapy including topical , UV light A, narrowband UV B, and UV light B.

Exclusion criteria

Exclusion Criteria:

-Use of systemic or topical therapy for contact or atopic dermatitis within 30 days of screening

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo.

    Drug: Placebo

  • Active comparator
    Tacrolimus

    Tacrolimus 0.1% ointment twice daily for 28 days.

    Drug: Tacrolimus

  • Experimental
    OPA-15406

    Drug: OPA-15406

Interventions

  • 0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days

  • 0.1% concentration of tacrolimus.

    Also known as: Protopic

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of subjects with AEs, SAEs, and % of clinically relevant changes from baseline in Draize Scale, physical examinations, vital signs, laboratory assessments, and electrocardiograms.

    Time frame: 28 days

  2. Measurement of drug levels in the blood of treated patients

    Time frame: 28 days

Secondary outcomes

  1. Investigator's Global Assessment (IGA) of Disease Severity at Week 4

    Time frame: 28 Days

07

Study locations

12 sites
  • Mobile, Alabama 36608, United States
  • Hot Springs, Arizona 71913, United States
  • Irvine, California 92697, United States
  • Orange Park, Florida 32073, United States
  • Tampa, Florida 33609, United States
  • Carmel, Indiana 46032, United States
  • Berlin, New Jersey 08009, United States
  • High Point, North Carolina 27262, United States
  • Portland, Oregon 97210, United States
  • College Station, Texas 77845, United States
  • Dallas, Texas 75230, United States
  • San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2012
First posted
Oct 5, 2012
Start
Aug 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Jan 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01702181
Responsible party
Sponsor
First posted
Oct 5, 2012
Start date
Aug 2012
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Jan 17, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion